Healwell AI Builds Commercial Momentum on a Foundation of 47 Peer-Reviewed Studies

Healwell AI transitions from research to revenue, securing multi-million dollar contracts and achieving positive adjusted EBITDA, backed by 47 peer-reviewed studies for its DARWEN platform.

In the competitive healthcare AI sector, peer-reviewed validation is a critical currency. Healwell AI has significantly bolstered its position, announcing that its DARWEN™ platform is now supported by 47 validated studies. This substantial scientific foundation is being paired with tangible commercial contracts, signaling a move from pure research to market execution.

Commercial Contracts Signal Market Adoption

The company's scientific credibility is translating into real-world business. In early March, Healwell secured a multi-year software agreement valued in the tens of millions of dollars with a U.S. Health Information Exchange. This deal was won through its subsidiaries, Orion Health and VeroSource. The platform will connect hospitals, laboratories, public health agencies, and private providers across an entire U.S. state, delivering real-time data on patient admissions, discharges, and lab results to clinicians.

Revenue streams are now active, with contracts currently generating income from Canada, the United States, and the Middle East. Furthermore, the company has outlined a rollout plan for its Amadeus-AI platform, targeting a North American launch in the first half of 2026, followed by an international expansion in the second half of the year.

Research Expansion Across Therapeutic Areas

On the scientific front, Healwell presented new research at the European Crohn's and Colitis Organisation congress on March 12. The study, published in the Journal of Crohn's and Colitis, demonstrates how the DARWEN™ platform utilizes AI-processed data from Canadian patient programs to generate real-world evidence for pharmaceutical partners in the United States.

The company's research pipeline is robust, with three additional conference presentations already confirmed for 2026. These will cover diabetes, dermatology, and inflammatory bowel disease, each conducted in collaboration with global pharmaceutical firms. The strategic value is clear: every new publication extends the platform's clinical credibility into new therapeutic areas, making it an increasingly indispensable tool for both hospital networks and drug developers.

Financial Snapshot and Upcoming Catalysts

Recent financial data from the third quarter of 2025 provides a progress report. Revenue from continuing operations reached $30.4 million. Notably, the adjusted EBITDA turned positive, coming in at $0.7 million—a significant improvement from a loss of $2.8 million in the same period the previous year. The net loss from continuing operations was reported at $16 million.

Investors are awaiting several key near-term events. Healwell will release its complete 2025 financial results on March 19, 2026. An analyst conference call is scheduled for the following day, March 20. Just three days later, on March 23, CEO Dr. Alexander Dobranowski is set to present at the 38th Annual ROTH Conference in Dana Point.

Currently, Healwell's share price trades approximately 48% below its 52-week high from March 2025. The market appears to be watching for conclusive evidence that the company's growing portfolio of studies will consistently translate into stronger financial performance.